hotspot -WSS

hotspot

author：hotspot 2025-09-27 21:27:50 - browse：9

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Custom gene therapy hints at new path for rare disease treatments

focus

WSS

WHO calls for emergency meeting on new China virus, as cases spread

State of the Union pitch: Bigger Medicare drug price negotiations

Florida health officials providing scant details on measles cases

Stem cell biologist probes earliest stages of human development

Doctors find melanoma drugs effective against rare brain cancer

As digital health tech proliferates, a new institute aims to cut through hype

leisure time

hotspot

knowledge

New air purifier tech could be key to improving indoor air quality

Group opposing PBM reform sets lobbying record

Duchenne breakthrough therapy leaves behind pioneering families

At Orexo, a ‘turning point’ for everything but digital health

Heart attack and stroke risk calculators need revising

He's 19 months old and has one of the world’s rarest diseases

How to save PrEP access — and even expand it

A public scorecard can help hold safety

Supreme Court strikes down use of affirmative action

Ancient Greek ideas underpin modern concepts of pregnancy

Wikipedia

How Medicaid coverage policies for immigrants impact new moms

Why Talkspace is targeting Medicare, a tricky market

$1 billion proposal to grow Boston, Massachusetts biotech

Startup Neumora takes a novel depression drug to Phase 3

Ozempic has benefits for kidney disease as well as diabetes

At Orexo, a ‘turning point’ for everything but digital health

entertainment

focus

focus

hotspot